4//SEC Filing
Gentilcore Douglas J 4
Accession 0002052524-25-000003
CIK 0001722964other
Filed
Sep 17, 8:00 PM ET
Accepted
Sep 18, 9:29 PM ET
Size
7.5 KB
Accession
0002052524-25-000003
Insider Transaction Report
Form 4
Gentilcore Douglas J
SVP, Danyelza Bus. Unit Head
Transactions
- Disposition to Issuer
Employee Stock Option (right to buy)
2025-09-16−142,600→ 0 totalExercise: $6.16Exp: 2035-01-17→ Common Stock (142,600 underlying)
Footnotes (2)
- [F1]Pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated as of August 4, 2025, by and among Y-mAbs Therapeutics, Inc. (the "Issuer"), Yosemite Merger Sub, Inc. ("Purchaser"), Perseus BidCo US, Inc., a Delaware corporation ("Parent"), and Stark International Lux, a Luxembourg private limited liability company ("Ultimate Parent"), on September 16, 2025, Purchaser completed a tender offer for shares of common stock of the Issuer (each, a "Share") and thereafter merged with and into the Issuer, with the Issuer continuing as the surviving corporation and an indirect wholly owned subsidiary of Parent (the "Merger").
- [F2]At the effective time of the Merger (being such date and at such time as the certificate of merger in respect of the Merger was duly filed with the Secretary of State of the State of Delaware in accordance with the DGCL) (the "Effective Time"), pursuant to the Merger Agreement, each stock option ("Option") outstanding as of immediately prior to the Effective Time, whether vested or unvested, was cancelled and converted into the right to receive cash, without interest, equal to the product of (a) the total number of Shares subject to such Option immediately prior to the Effective Time, multiplied by (b) the excess of the Merger Consideration (the right to receive $8.60 per Share, in cash, without interest, subject to any applicable withholding of taxes (the "Merger Consideration")) over the exercise price payable per Share under such Option. Any Options with an exercise price equal to or in excess of the Merger Consideration were cancelled for no consideration.
Documents
Issuer
Y-mAbs Therapeutics, Inc.
CIK 0001722964
Entity typeother
Related Parties
1- filerCIK 0002052524
Filing Metadata
- Form type
- 4
- Filed
- Sep 17, 8:00 PM ET
- Accepted
- Sep 18, 9:29 PM ET
- Size
- 7.5 KB